Sanofi-Aventis Launches ClikSTAR In Canada

Sanofi-Aventis has launched ClikSTAR in Canada. The Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels.

The company claims that the reusable pen has all the benefits of the pre-filled Lantus SoloSTAR and Apidra SoloSTAR delivery device, including a low injection force, a dial and dose setting that allows patients to administer doses from one to 80 units in a single injection, numbering that is both large and clear that lessens the possibility of injection error, and a dial back safety feature to correct dose selection errors.

In addition to Canada, the new pen is being launched in Switzerland, Greece and the Netherlands. ClikSTAR is currently being reviewed by the FDA.

Laurent-Didier Jacobs, vice-president of medical affairs at Sanofi-Aventis Canada, said: “With the introduction of Lantus ClikSTAR, we offer a new device for patients with type 1 and type 2 diabetes, explaining that Lantus ClikSTAR ideally complements the previously launched Lantus SoloSTAR and Apidra SoloSTAR pre-filled insulin pens. The Lantus SoloSTAR and Apidra SoloSTAR ready-to-use insulin pens were launched to respond to the different lifestyle needs of patients by providing them with an easier way to self-administer their insulin injections. For this reason, SoloSTAR will continue to be available for patients who find the process of loading or changing insulin cartridges burdensome and even difficult.”